Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

Alzheimer's disease, a type of dementia that profoundly alters a person’s memory and cognitive function, affects an estimated 6.7 million U.S. adults at least 65 years old, according to the ...

New research provides the first direct evidence that brain lesions causing secondary psychosis map to a common brain circuit ...

Here’s a recap of our 10 most-read F&B stories from January 2025, including top trends, emerging categories and regulations ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and ...

About Evrysdi Evrysdi is an SMN2-splicing modifier designed to increase functional SMN protein production. With the introduction of a new tablet formulation, Evrysdi now offers an alternative ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

Industry executives sounded somewhat optimistic at the Mido eyewear trade show as the category proves resilient against a ...

Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once-daily oral treatment for adults with ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for troriluzole for the treatment of adults with ...

Cannabis pouches emerge as an alternative to smoking, but can they match Zyn's success? Experts weigh in on market potential ...